Circadian System Functionality, Hippocampal Oxidative Stress, and Spatial Memory in the APPswe/PS1dE9 Transgenic Model of Alzheimer Disease: Effects of Melatonin or Ramelteon

REFERENCES

• Arendash GW, King DL, Gordon MN, Morgan D, Hatcher JM, Hope CE, Diamond DM. (2001). Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res. 891:42–53.
   PubMed Web of Science ®Google Scholar
• Bliwise DL. (1994). What is sundowning? J. Am. Geriatr. Soc. 42:1009–1011.
   PubMed Web of Science ®Google Scholar
• Boutin JA, Audinot V, Ferry G, Delagrange P. (2005). Molecular tools to study melatonin pathways and actions. Trends Pharmacol. Sci. 26:412–419.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Feng Z, Zhang QZ, Zhang JT. (2006). Beneficial effects of melatonin in experimental models of Alzheimer disease. Acta Pharmacol. Sin. 27:129–139.
   PubMedGoogle Scholar
• desRosiers G, Hodges JR, Berrios G. (1995). The neuropsychological differentiation of patients with very mild Alzheimer's disease and/or major depression. J. Am. Geriatr. Soc. 43:1256–1263.
   PubMed Web of Science ®Google Scholar
• Dragicevic N, Copes N, O'Neal-Moffitt G, Jin J, Buzzeo R, Mamcarz M, Tan J, Cao C, Olcese JM, Arendash GW, Bradshaw PC. (2011). Melatonin treatment restores mitochondrial function in Alzheimer's mice: a mitochondrial protective role of melatonin membrane receptor signaling. J. Pineal Res. 51:75–86.
   PubMed Web of Science ®Google Scholar
• Duyckaerts C, Potier MC, Delatour B. (2008). Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol. 115:5–38.
   PubMed Web of Science ®Google Scholar
• Duyckaerts C, Delatour B, Potier MC. (2009). Classification and basic pathology of Alzheimer disease. Acta Neuropathol. 118:5–36.
   PubMed Web of Science ®Google Scholar
• Ennaceur A, Michalikova S, Bradford A, Ahmed S. (2005). Detailed analysis of the behavior of Lister and Wistar rats in anxiety, object recognition and object location tasks. Behav. Brain Res. 159:247–266.
   PubMed Web of Science ®Google Scholar
• Feng Z, Qin C, Chang Y, Zhang JT. (2006). Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer's disease. Free Radic. Biol. Med. 40:101–109.
   PubMed Web of Science ®Google Scholar
• Fisher SP, Davidson K, Kulla A, Sugden D. (2008). Acute sleep-promoting action of the melatonin agonist, ramelteon, in the rat. J. Pineal Res. 45:125–132.
   PubMedGoogle Scholar
• Foster CE, Bianchet MA, Talalay P, Faig M, Amzel LM. (2000). Structures of mammalian cytosolic quinone reductases. Free Radic. Biol. Med. 29:241–245.
   PubMed Web of Science ®Google Scholar
• Frye CA, Walf AA. (2008). Progesterone to ovariectomized mice enhances cognitive performance in the spontaneous alternation, object recognition, but not placement, water maze, and contextual and cued conditioned fear tasks. Neurobiol. Learn. Mem. 90:171–177.
   PubMedGoogle Scholar
• Furio AM, Cutrera RA, Castillo Thea V, Pérez Lloret S, Riccio P, Caccuri RL, Brusco LL, Cardinali DP. (2002). Effect of melatonin on changes in locomotor activity rhythm of Syrian hamsters injected with beta amyloid peptide 25–35 in the suprachiasmatic nuclei. Cell. Mol. Neurobiol. 22:699–709.
   PubMedGoogle Scholar
• Galano A, Tan DX, Reiter RJ. (2011). Melatonin as a natural ally against oxidative stress: a physicochemical examination. J. Pineal Res. 51:1–16.
   PubMed Web of Science ®Google Scholar
• García T, Ribes D, Colomina MT, Cabré M, Domingo JL, Gómez M. (2009). Evaluation of the protective role of melatonin on the behavioral effects of aluminum in a mouse model of Alzheimer's disease. Toxicology 265:49–55.
   PubMedGoogle Scholar
• Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW, Connor K, Melachrino J, O'Callaghan JP, Morgan D. (2002). Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp. Neurol. 173:183–195.
   PubMed Web of Science ®Google Scholar
• Gorman MR, Yellon S. (2010). Lifespan daily locomotor activity rhythms in a mouse model of amyloid-induced neuropathology. Chronobiol. Int. 27:1159–1177.
   PubMed Web of Science ®Google Scholar
• Gruart A, López-Ramos JC, Muñoz MD, Delgado-García JM. (2008). Aged wild-type and APP, PS1, and APP+PS1 mice present similar deficits in associative learning and synaptic plasticity independent of amyloid load. Neurobiol. Dis. 30:439–450.
   PubMedGoogle Scholar
• Hardy J. (1997). Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 20:154–159.
   PubMed Web of Science ®Google Scholar
• Hirai K, Kita M, Ohta H, Nishikawa H, Fujiwara Y, Ohkawa S, Miyamoto M. (2005). Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats. J. Biol. Rhythms 20:27–37.
   PubMed Web of Science ®Google Scholar
• Howlett DR, Richardson JC, Austin A, Parsons AA, Bate ST, Davies DC, Gonzalez MI. (2004). Cognitive correlates of Aβ deposition in male and female mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. Brain Res. 1017:130–136.
   PubMed Web of Science ®Google Scholar
• Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR. (2004). Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase. Hum. Mol. Genet. 13:159–170.
   PubMed Web of Science ®Google Scholar
• Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S, Kawamata Y, Hinuma S, Miyamoto M. (2005). Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 48:301–310.
   PubMed Web of Science ®Google Scholar
• Lax P, Otalora BB, Esquiva G, Rol M de L, Madrid JA, Cuenca N. (2011). Circadian dysfunction in P23H rhodopsin transgenic rats: effects of exogenous melatonin. J. Pineal Res. 50:183–191.
   PubMed Web of Science ®Google Scholar
• Lee JH, Bliwise DL, Ansari FP, Goldstein FC, Cellar JS, Lah JJ, Levey AI. (2007). Daytime sleepiness and functional impairment in Alzheimer disease. Am. J. Geriatr. Psychiatry 15:620–626.
   PubMed Web of Science ®Google Scholar
• Lewy AJ, Bauer VK, Ahmed S, Thomas KH, Cutler NL, Singer CM, Moffit MT, Sack RL. (1998). The human phase response curve (PRC) to melatonin is about 12 hours out of phase with the PRC to light. Chronobiol. Int. 15:71–83.
   PubMed Web of Science ®Google Scholar
• Mahlberg R, Kunz D, Sutej I, Kühl KP, Hellweg R. (2004). Melatonin treatment of day-night rhythm disturbances and sundowning in Alzheimer disease: an open-label pilot study using actigraphy. J. Clin. Psychopharmacol. 24:456–459.
   PubMedGoogle Scholar
• Marques SC, Oliveira CR, Outeiro TF, Pereira CM. (2010). Alzheimer's disease: the quest to understand complexity. J. Alzheimer Dis. 21:373–383.
   PubMedGoogle Scholar
• Mathes AM, Kubulus D, Waibel L, Weiler J, Heymann P, Wolf B, Rensing H. (2008). Selective activation of melatonin receptors with ramelteon improves liver function and hepatic perfusion after hemorrhagic shock in rat. Crit. Care Med. 36:2863–2870.
   PubMed Web of Science ®Google Scholar
• Merlino G, Piani A, Gigli GL, Cancelli I, Rinaldi A, Baroselli A, Serafini A, Zanchettin B, Valente M. (2010). Daytime sleepiness is associated with dementia and cognitive decline in older Italian adults: a population-based study. Sleep Med. 11:372–377.
   PubMedGoogle Scholar
• Minkeviciene R, Banerjee P, Tanila H. (2004). Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease. J. Pharmacol. Exp. Ther. 311:677–682.
   PubMed Web of Science ®Google Scholar
• Miyamoto M. (2006). Effect of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist, on motor performance in mice. Neurosci. Lett. 402:201–204.
   PubMedGoogle Scholar
• Olcese JM, Cao C, Mori T, Mamcarz MB, Maxwell A, Runfeldt MJ, Wang L, Zhang C, Lin X, Zhang G, Arendash GW. (2009). Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. J. Pineal Res. 47:82–96.
   PubMed Web of Science ®Google Scholar
• Ortiz-Tudela E, Martinez-Nicolas A, Campos M, Rol MÁ, Madrid JA. (2010). A new integrated variable based on thermometry, actimetry and body position (TAP) to evaluate circadian system status in humans. PLoS Comput. Biol. 6:e1000996.
   PubMed Web of Science ®Google Scholar
• Otálora BB, Madrid JA, Alvarez N, Vicente V, Rol MA. (2008). Effects of exogenous melatonin and circadian synchronization on tumor progression in melanoma-bearing C57BL6 mice. J. Pineal Res. 44:307–315.
   PubMedGoogle Scholar
• Pappolla MA, Chyan YJ, Poeggeler B, Frangione B, Wilson G, Ghiso J, Reiter RJ. (2000). An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease. J. Neural Transm. 107:203–231.
   PubMed Web of Science ®Google Scholar
• Poeggeler B, Thuermann S, Dose A, Schoenke M, Burkhardt S, Hardeland R. (2002). Melatonin's unique radical scavenging properties—roles of its functional substituents as revealed by a comparison with its structural analogs. J. Pineal Res. 33:20–30.
   PubMed Web of Science ®Google Scholar
• Portaluppi F, Smolensky MH, Touitou Y. (2010). Ethics and methods for biological rhythm research on animals and human beings. Chronobiol. Int. 27:1911–1929.
   PubMed Web of Science ®Google Scholar
• Quinn J, Kulhanek D, Nowlin J, Jones R, Praticò D, Rokach J, Stackman R. (2005). Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials. Brain Res. 1037:209–213.
   PubMed Web of Science ®Google Scholar
• Redman JR, Armstrong SM. (1988). Reentrainment of rat circadian activity rhythms: effects of melatonin. J. Pineal Res. 5:203–215.
   PubMed Web of Science ®Google Scholar
• Reiserer RS, Harrison FE, Syverud DC, McDonald MP. (2007). Impaired spatial learning in the APPSwe+PSEN1DeltaE9 bigenic mouse model of Alzheimer's disease. Genes Brain Behav. 6:54–65.
   PubMed Web of Science ®Google Scholar
• Reiter RJ, Paredes SD, Manchester LC, Tan DX. (2009). Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Crit. Rev. Biochem. Mol. Biol. 44:175–200.
   PubMed Web of Science ®Google Scholar
• Reiter RJ, Tan DX, Fuentes-Broto L. (2010). Melatonin: a multitasking molecule. Prog. Brain Res. 181:127–151.
   PubMed Web of Science ®Google Scholar
• Satlin A, Volicer L, Stopa EG, Harper D. (1995). Circadian locomotor activity and core-body temperature rhythms in Alzheimer's disease. Neurobiol. Aging 16:765–771.
   PubMed Web of Science ®Google Scholar
• Savaskan E, Olivieri G, Meier F, Brydon L, Jockers R, Ravid R, Wirz-Justice A, Müller-Spahn F. (2002). Increased melatonin 1a-receptor immunoreactivity in the hippocampus of Alzheimer's disease patients. J. Pineal Res. 32:59–62.
   PubMed Web of Science ®Google Scholar
• Savaskan E, Ayoub MA, Ravid R, Angeloni D, Fraschini F, Meier F, Eckert A, Müller-Spahn F, Jockers R. (2005). Reduced hippocampal MT2 melatonin receptor expression in Alzheimer's disease. J. Pineal Res. 38:10–16.
   PubMed Web of Science ®Google Scholar
• Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, Wong MP, Price DL, Tang F, Markowska AL, Borchelt DR. (2005). Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol. Dis. 18:602–617.
   PubMed Web of Science ®Google Scholar
• Scullion GA, Kendall DA, Marsden CA, Sunter D, Pardon MC. (2011). Chronic treatment with the α(2)-adrenoceptor antagonist fluparoxan prevents age-related deficits in spatial working memory in APP×PS1 transgenic mice without altering β-amyloid plaque load or astrocytosis. Neuropharmacology 60:223–234.
   PubMedGoogle Scholar
• Sterniczuk R, Dyck RH, Laferla FM, Antle MC. (2010). Characterization of the 3×Tg-AD mouse model of Alzheimer's disease: part 1. Circadian changes. Brain Res. 1348:139–148.
   PubMed Web of Science ®Google Scholar
• Tan DX, Chen LD, Poeggeler B, Manchester LC, Reiter RJ. (1993). Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocr. J. 1:57–60.
   Google Scholar
• Tomás-Zapico C, Coto-Montes A. (2005). A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes. J. Pineal Res. 39:99–104.
   PubMed Web of Science ®Google Scholar
• Valentinuzzi VS, Scarbrough K, Takahashi JS, Turek FW. (1997). Effects of aging on the circadian rhythm of wheel-running activity in C57BL/6 mice. Am. J. Physiol. 273:R1957–R1964.
   PubMed Web of Science ®Google Scholar
• van Someren EJ, Hagebeuk EE, Lijzenga C, Scheltens P, de Rooij SE, Jonker C, Pot AM, Mirmiran M, Swaab DF. (1996). Circadian rest-activity rhythm disturbances in Alzheimer's disease. Biol. Psychiatry 40:259–270.
   PubMed Web of Science ®Google Scholar
• Vitiello MV, Bliwise DL, Prinz PN. (1992). Sleep in Alzheimer's disease and the sundown syndrome. Neurology 42:83–93.
   PubMed Web of Science ®Google Scholar
• Vivanco P, Ortiz V, Rol MA, Madrid JA. (2007). Looking for the keys to diurnality downstream from the circadian clock: role of melatonin in a dual-phasing rodent, Octodon degus. J. Pineal Res. 42:280–290.
   PubMedGoogle Scholar
• Vloeberghs E, Van Dam D, Engelborghs S, Nagels G, Staufenbiel M, De Deyn PP. (2004). Altered circadian locomotor activity in APP23 mice: a model for BPSD disturbances. Eur. J. Neurosci. 20:2757–2766.
   PubMed Web of Science ®Google Scholar
• Volicer L, Harper DG, Manning BC, Goldstein R, Satlin A. (2001). Sundowning and circadian rhythms in Alzheimer's disease. Am. J. Psychiatry 158:704–711.
   PubMed Web of Science ®Google Scholar
• Wisor JP, Edgar DM, Yesavage J, Ryan HS, McCormick CM, Lapustea N, Murphy GM (2005). Sleep and circadian abnormalities in a transgenic mouse model of Alzheimer's disease: a role for cholinergic transmission. Neuroscience 131:375–385.
   PubMed Web of Science ®Google Scholar
• Wong SH, Knight JA, Hopfer SM, Zaharia O, Leach CN , Sunderman FW Jr. (1987). Lipoperoxides in plasma as measured by liquid-chromatographic separation of malondialdehyde-thiobarbituric acid adduct. Clin. Chem. 33:214–220.
   PubMed Web of Science ®Google Scholar
• Wu YH, Swaab DF. (2005). The human pineal gland and melatonin in aging and Alzheimer's disease. J. Pineal Res. 38:145–152.
   PubMed Web of Science ®Google Scholar
• Wu YH, Swaab DF. (2007). Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer's disease. Sleep Med. 8:623–636.
   PubMed Web of Science ®Google Scholar
• Wu YH, Zhou JN, Van Heerikhuize J, Jockers R, Swaab DF. (2007). Decreased MT1 melatonin receptor expression in the suprachiasmatic nucleus in aging and Alzheimer's disease. Neurobiol. Aging 28:1239–1247.
   PubMed Web of Science ®Google Scholar
• Yukuhiro N, Kimura H, Nishikawa H, Ohkawa S, Yoshikubo S, Miyamoto M. (2004). Effects of ramelteon (TAK-375) on nocturnal sleep in freely moving monkeys. Brain Res. 1027:59–66.
   PubMed Web of Science ®Google Scholar